EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association of M2BPGi with Subclinical Atherosclerosis in Metabolic Dysfunction-Associated Steatotic Liver Disease

Yong Jun Choi iD, Kyunghoon Lee iD, Han-Ik Cho, Jooheon Park iD, Myung Geun Shin iD, Ye Seol Lee, Sun Cho, Eun-Hee Nah iD

Metabolites · 24.07.2026 · 16 (8) · 524

DOI: 10.3390/metabo16080524 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Metabolites, online erschienen am 24.07.2026. Verfasst von Yong Jun Choi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Chonnam National University Hwasun Hospital, Hwasun 58128, Republic of Korea. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sysmex Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a systemic metabolic disorder associated with an elevated risk of cardiovascular disease. Mac-2 binding protein glycosylation isomer (M2BPGi), a noninvasive serum biomarker of hepatic fibrosis, has also been linked to adverse metabolic and cardiovascular outcomes. However, the association between serum M2BPGi levels and subclinical coronary atherosclerosis in individuals with MASLD remains unclear. We investigated the association between serum M2BPGi levels and coronary artery calcium score (CACS), an established imaging marker of subclinical atherosclerosis, in individuals with MASLD.

Methods

This retrospective cross-sectional study included 6514 adults with MASLD who underwent health screening examinations between 2020 and 2025. Participants were categorized into quartiles according to serum M2BPGi levels: Q1 ( 0. Multivariable logistic regression analysis was performed after adjustment for age, sex, smoking status, liver enzymes, adiposity, dysglycemia, blood pressure, and lipid profile. Multivariable ordinal logistic regression analysis was additionally performed to evaluate the association between M2BPGi levels and CAC severity.

Results

The prevalence of CAC increased progressively across M2BPGi quartiles (39.4%, 45.3%, 48.5%, and 57.4% for Q1–Q4, respectively; p < 0.001). In multivariable logistic regression analysis, participants in the highest M2BPGi quartile had significantly higher odds of CAC presence than those in the lowest quartile (OR, 1.32; 95% CI, 1.10–1.58; p = 0.0035). Higher M2BPGi quartiles were also independently associated with greater CAC severity in multivariable ordinal logistic regression analysis (OR, 1.33; 95% CI, 1.13–1.57; p = 0.0007 for Q4 vs. Q1).

Conclusions

Higher serum M2BPGi levels were independently associated with both the presence and severity of CAC in individuals with MASLD. These findings suggest that M2BPGi may serve as a potential biomarker for identifying individuals with MASLD at increased risk of subclinical atherosclerosis and may complement conventional cardiovascular risk assessment.

Schlagwörter

Stichwörter der Autor:innen

Mac-2 binding protein glycosylation isomercardiovascular riskcoronary artery calcium scorehepatic fibrosismetabolic dysfunction-associated steatotic liver disease

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Chonnam National University Hwasun Hospital, Hwasun 58128, Republic of Korea.
  • MEDIcheck LAB, Korea Association of Health Promotion, Seoul 07572, Republic of Korea.
  • MediCheck Research Institute, Korea Association of Health Promotion, Seoul 07572, Republic of Korea.

ORCID-Profile: Yong Jun Choi, Kyunghoon Lee, Jooheon Park, Myung Geun Shin, Eun-Hee Nah

Förderung

  • Sysmex Korea

Zitieren

APA

Choi, Y. J., Lee, K., Cho, H. I., Park, J., Shin, M. G., Lee, Y. S., Cho, S., & Nah, E. H. (2026). Association of M2BPGi with Subclinical Atherosclerosis in Metabolic Dysfunction-Associated Steatotic Liver Disease. Metabolites, 16(8), 524. https://doi.org/10.3390/metabo16080524

Vancouver

Choi YJ, Lee K, Cho HI, Park J, Shin MG, Lee YS, et al. Association of M2BPGi with Subclinical Atherosclerosis in Metabolic Dysfunction-Associated Steatotic Liver Disease. Metabolites. 2026;16(8):524. doi:10.3390/metabo16080524

BibTeX
@article{Choi2026,
  author = {Choi, Yong Jun and Lee, Kyunghoon and Cho, Han-Ik and Park, Jooheon and Shin, Myung Geun and Lee, Ye Seol and Cho, Sun and Nah, Eun-Hee},
  title = {Association of M2BPGi with Subclinical Atherosclerosis in Metabolic Dysfunction-Associated Steatotic Liver Disease},
  journal = {Metabolites},
  year = {2026},
  volume = {16},
  number = {8},
  pages = {524},
  doi = {10.3390/metabo16080524}
}
Kostenlos starten →